Literature DB >> 35957948

Multivariable Models Based on Baseline Imaging Features and Clinicopathological Characteristics to Predict Breast Pathologic Response after Neoadjuvant Chemotherapy in Patients with Breast Cancer.

Peixian Chen1, Chuan Wang2, Ruiliang Lu3, Ruilin Pan1, Lewei Zhu1, Dan Zhou1, Guolin Ye1.   

Abstract

Introduction: Currently, the accurate evaluation and prediction of response to neoadjuvant chemotherapy (NAC) remains a great challenge. We developed several multivariate models based on baseline imaging features and clinicopathological characteristics to predict the breast pathologic complete response (pCR).
Methods: We retrospectively collected clinicopathological and imaging data of patients who received NAC and subsequent surgery for breast cancer at our hospital from June 2014 till September 2020. We used mammography, ultrasound, and magnetic resonance imaging (MRI) to investigate the breast tumors at baseline.
Results: A total of 308 patients were included and 111 patients achieved pCR. The HER-2 status and Ki-67 index were significant factors for pCR on univariate analysis and in all multivariate models. Among the prediction models in this study, the ultrasound plus MRI model performed best, producing an area under curve of 0.801 (95% CI 0.749-0.852), a sensitivity of 0.797, and a specificity of 0.676.
Conclusion: Among the multivariable models constructed in this study, the ultrasound plus MRI model performed best in predicting the probability of pCR after NAC. Further validation is required before it is generalized.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Breast cancer; Magnetic resonance imaging; Mammography; Neoadjuvant chemotherapy; Ultrasound

Year:  2021        PMID: 35957948      PMCID: PMC9247529          DOI: 10.1159/000521638

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.268


  30 in total

1.  Multiparametric MRI-based radiomics analysis for prediction of breast cancers insensitive to neoadjuvant chemotherapy.

Authors:  Qianqian Xiong; Xuezhi Zhou; Zhenyu Liu; Chuqian Lei; Ciqiu Yang; Mei Yang; Liulu Zhang; Teng Zhu; Xiaosheng Zhuang; Changhong Liang; Zaiyi Liu; Jie Tian; Kun Wang
Journal:  Clin Transl Oncol       Date:  2019-04-11       Impact factor: 3.405

2.  Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.

Authors:  R F D van la Parra; A B Tadros; C M Checka; G M Rauch; A Lucci; B D Smith; S Krishnamurthy; V Valero; W T Yang; H M Kuerer
Journal:  Br J Surg       Date:  2018-02-21       Impact factor: 6.939

3.  Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer.

Authors:  F Denis; A V Desbiez-Bourcier; C Chapiron; F Arbion; G Body; L Brunereau
Journal:  Eur J Surg Oncol       Date:  2004-12       Impact factor: 4.424

4.  Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response.

Authors:  H Preibsch; L Wanner; S D Bahrs; B M Wietek; K C Siegmann-Luz; E Oberlecher; M Hahn; A Staebler; K Nikolaou; B Wiesinger
Journal:  Eur Radiol       Date:  2015-09-17       Impact factor: 5.315

5.  A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.

Authors:  Keith N Ogston; Iain D Miller; Simon Payne; Andrew W Hutcheon; Tarun K Sarkar; Ian Smith; A Schofield; Steven D Heys
Journal:  Breast       Date:  2003-10       Impact factor: 4.380

6.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

7.  Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy.

Authors:  Viviana Londero; Massimo Bazzocchi; Chiara Del Frate; Fabio Puglisi; Carla Di Loreto; Giuliana Francescutti; Chiara Zuiani
Journal:  Eur Radiol       Date:  2004-02-18       Impact factor: 5.315

8.  Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer.

Authors:  A E Ring; I E Smith; S Ashley; L G Fulford; S R Lakhani
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

9.  Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer.

Authors:  Seho Park; Jung Hyun Yoon; Joohyuk Sohn; Hyung Seok Park; Hee Jung Moon; Min Jung Kim; Eun-Kyung Kim; Seung Il Kim; Byeong-Woo Park
Journal:  PLoS One       Date:  2016-02-11       Impact factor: 3.240

10.  Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Authors:  Rita A Mukhtar; Christina Yau; Mark Rosen; Vickram J Tandon; Nola Hylton; Laura J Esserman
Journal:  Ann Surg Oncol       Date:  2013-06-19       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.